Plump Andrew Stewart
Officer at TAK
- Sold, on record
- $5.3M
- Dollars the filings state
- Form 4 sales
- 3
- Latest Sep 2, 2026
- Form 144 notices
- 6
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- TAKTAKEDA PHARMACEUTICAL CO LTDOfficer
Sales by reason
Form 4 sales per month, last 12 months.
Timeline
- 1 Form 144 notice TAKNoticeJul 10, 2024 2024
Filed to sell 121,125 shares ($1.6M)
Plump Andrew Stewart, President, Research & Development
No 10b5-1 planFirst sale on recordFiling
- 2 Form 144 notice TAKNoticeJul 9, 2025 +364 days
Filed to sell 169,313 shares ($2.6M)
Plump Andrew Stewart, President, Research & Development
No 10b5-1 planFirst sale on recordFiling
- 3 Form 144 notice TAKNoticeJul 13, 2026 +369 days
Filed to sell 179,239 shares ($3M)
Plump Andrew Stewart, President, Research & Development
No 10b5-1 planFirst sale on recordFiling
- 4 Form 4 sale TAKNo planAug 10, 2026 +28 days
Sold 165,393 shares at $17.10 ($2.8M)
Plump Andrew Stewart, President, R&D
No 10b5-1 planSold 17.7% of holdings ($15.9M position)766,569 shares leftFirst sale on recordFollows a Form 144Filing
- 5 Form 144 notice TAKNoticeAug 19, 2026 +9 days
Filed to sell 19,651 shares ($363k)
Plump Andrew Stewart, Officer
10b5-1 planFiling
- 6 Form 4 sale TAKRoutineAug 19, 2026 same day
Sold 19,651 shares at $18.49 ($363k)
Plump Andrew Stewart, President, R&D
10b5-1 planSold 7% of holdings ($5.2M position)261,656 shares leftFollows a Form 144Filing
- 7 Form 144 notice TAKNoticeSep 2, 2026 +14 days
Filed to sell 116,191 shares ($2.1M)
Plump Andrew Stewart, Officer
10b5-1 planFiling
- 8 Form 4 sale TAKRoutineSep 2, 2026 same day
Sold 116,191 shares at $18.49 ($2.1M)
Plump Andrew Stewart, President, R&D
10b5-1 planSold 44.4% of holdings ($4.8M position)145,465 shares leftFollows a Form 144Filing
Every transaction
Loading transactions…
Sales and notices (9)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | Sep 3, 2026 | TAK | President, R&D | Form 4 sale | 116,191 | $2.1M | 44.4% | Routine | SEC |
| Sep 2, 2026 | Sep 2, 2026 | TAK | Officer | Form 144 notice | 116,191 | $2.1M | Notice | SEC | |
| Aug 19, 2026 | Aug 21, 2026 | TAK | President, R&D | Form 4 sale | 19,651 | $363k | 7.0% | Routine | SEC |
| Aug 19, 2026 | Aug 19, 2026 | TAK | Officer | Form 144 notice | 19,651 | $363k | Notice | SEC | |
| Aug 10, 2026 | Aug 12, 2026 | TAK | President, R&D | Form 4 sale | 165,393 | $2.8M | 17.7% | No plan | SEC |
| Jul 13, 2026 | Jul 13, 2026 | TAK | President, Research & Development | Form 144 notice | 179,239 | $3M | Notice | SEC | |
| Jul 9, 2025 | Jul 9, 2025 | TAK | President, Research & Development | Form 144 notice | 169,313 | $2.6M | Notice | SEC | |
| Jul 10, 2024 | Jul 10, 2024 | TAK | President, Research & Development | Form 144 notice | 121,125 | $1.6M | Notice | SEC | |
| Jul 10, 2023 | Jul 10, 2023 | TAK | President, Research & Development | Form 144 notice | 138,264 | $2.1M | Notice | SEC |